Virus News and Research

Latest Virus News and Research

Ceregene commences enrollment in CERE-120 Phase 2b study for Parkinson's disease

Ceregene, Inc., a biopharmaceutical company, announced today that enrollment has begun in a new double-blind sham surgery-controlled Phase 2b study evaluating CERE-120 in Parkinson's disease patients. CERE-120 is a gene therapy product that delivers the neurotrophic factor neurturin to degenerating or dying dopamine neurons. Data from the first Phase 2 clinical trial of CERE-120 are being published later this year in Lancet Neurology (to appear online October 21, 2010).

20 Oct 2010

Study finds adipose dysfunction linked to steatosis, necroinflammation in G1 CHC patients

Researchers at the University of Palermo in Italy provide the evidence that a higher visceral adiposity index score-a new index of adipose dysfunction-has a direct correlation with viral load and is independently associated with both steatosis and necroinflammatory activity in patients with genotype 1 chronic hepatitis C (G1 CHC).

20 Oct 2010

Pharmacy graduate awarded national recognition for pioneering research in genetics

A young pharmacy graduate has been awarded national recognition for her pioneering research in the field of genetics which has the potential to treat diseases such as cancer and Parkinson's.

19 Oct 2010

Health care reform will lead more people to seek cancer prevention and risk-reduction services

More people will likely seek cancer prevention and risk-reduction services as a result of health care reform, say experts at The University of Texas MD Anderson Cancer Center.

19 Oct 2010

Cytheris initiates ORVACS Phase II clinical trial to study HIV infection

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of Phase II clinical trial of the company's investigative immunomodulatory agent, CYT107 (rhIL-7), in combination with two potent antiretroviral drugs represented by the integrase inhibitor raltegravir (ISENTRESS- Merck & Co.) and the CCR5 inhibitor, maraviroc (SELZENTRY- ViiV Healthcare).

19 Oct 2010

New research coalition to design first human trial of mosaic HIV vaccine candidate

Duke University Medical Center vaccine experts have assembled an international team of investigators to design and implement the first human trial of a mosaic HIV vaccine candidate, a novel strategy that attempts to counter one of the most daunting challenges in HIV vaccine design: the virus's extensive genetic diversity

19 Oct 2010

Micronics to advance PanNAT system for molecular diagnosis of infectious pathogens

Micronics, Inc., a development-stage company, today announced that the Department of Defense has awarded the company an Applied Research and Technology Development Award under the U.S. Army Medical Research and Materiel Command's Polytrauma and Blast Injury project for advancement of its PanNAT system for point-of-care molecular diagnosis of infectious pathogens.

19 Oct 2010

NeurogesX plans U.S. label expansion for Qutenza in HIV-associated neuropathy

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced plans to pursue a U.S. label expansion for Qutenza® (capsaicin) 8% patch to include patients with painful HIV-associated neuropathy (HIV-AN, also referred to as HIV-distal sensory polyneuropathy (HIV-DSP)).

19 Oct 2010

Egg allergy is no reason to avoid 2010-2011 flu vaccination

Having an egg allergy is not a reason to avoid getting the 2010-2011 flu vaccination.

19 Oct 2010

UCB presents P3, P4 clinical trial data for Crohn's disease at ACG Scientific Meeting

Findings from the PRECiSE 3 (P3) open label extension study for Cimzia, demonstrating the longest continuously running maintenance trial for an anti-TNF in Crohn's disease, will be exhibited at the 2010 Annual Scientific Meeting of the American College of Gastroenterology (ACG), taking place in San Antonio from October 15 – 20. Additionally, long-term efficacy data from the PRECiSE 4 (P4) clinical trial also will be presented at the meeting.

19 Oct 2010

BARACLUDE sNDA receives FDA approval for treatment of CHB patients with decompensated liver disease

Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) of BARACLUDE for the treatment of chronic hepatitis B (CHB) in adult patients with decompensated liver disease.

18 Oct 2010

GeoVax Labs contributes article for HIV vaccine

Robert T. McNally, Ph.D., president and CEO of GeoVax Labs, Inc. a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, has contributed an article on the search for an HIV vaccine to the October 15 issue of Genetic Engineering & Biotechnology News (GEN).

18 Oct 2010

NanoViricides' President delivers speech at ASNM Second Annual Conference

NanoViricides, Inc. announced today that the Company President was invited to and presented a talk at the Second Annual Conference of the American Society for NanoMedicine (ASNM).

18 Oct 2010

Major advance in treatment of brain disorders with external genes

In the October 17 issue of Nature Methods, researchers at Thomas Jefferson University describe how they can transfer genes into brain neurons intravenously, using a viral gene delivery vehicle (vector) that causes no side effects.

18 Oct 2010

ACG meeting to exhibit Cimzia data for Crohn's disease treatment

Studies and analyses of the Crohn's disease (CD) treatment Cimzia (certolizumab pegol) will be exhibited at the 2010 Annual Scientific Meeting of the American College of Gastroenterology, taking place in San Antonio from October 15 – 20.

18 Oct 2010

Biogen, Elan announce clinical utility data of two-step ELISA to detect anti-JCV antibodies

Biogen Idec and Elan Corporation, plc today announced data further supporting the potential clinical utility of an investigational assay that detects anti-JC virus (JCV) antibodies in human plasma or serum.

18 Oct 2010

Royal Cornwall Hospital receives grant to study Hepatitis E

Researchers from the Royal Cornwall Hospital in Truro have received a grant of -337,000 to carry out a two-year study with partners in Glasgow and Norwich into a rare form of Hepatitis - Hepatitis E. The grant has come from the Chief Scientist's Office for Scotland and will be divided between the three centres taking part in the study.

18 Oct 2010

Silver studded bacteria could help treat common cold and flu

Finally scientists may have found a potential cure for common cold. They have found “silver bullets” in yogurt that could destroy viruses and provide a cure for the flu and common cold.

18 Oct 2010

CDC: Hispanics more likely to have HIV than whites, but live longer

The Associated Press: Officials from the Centers for Disease Control and Prevention "estimate that 1 in 22 black Americans will be diagnosed with the AIDS virus in their lifetime — more than twice the risk for Hispanics and eight times that of whites. ... the lifetime risk is 1 in 52 for Hispanics, and 1 in 170 for whites. Asian-Americans had the lowest lifetime risk, at about 1 in 222" (10/14).

15 Oct 2010

OTIS urges pregnant women to get vaccinated against influenza

The Organization of Teratology Information Specialists (OTIS), a non-profit organization based at the University of California, San Diego with affiliates across North America, urges pregnant women to receive the influenza vaccine as soon as possible. The recommendation comes shortly after the American College of Obstetricians and Gynecologists Committee on Obstetric Practice issued new guidelines regarding the influenza vaccine during pregnancy.

15 Oct 2010

Virus News and Research

Latest Virus News and Research

Ceregene commences enrollment in CERE-120 Phase 2b study for Parkinson's disease

Study finds adipose dysfunction linked to steatosis, necroinflammation in G1 CHC patients

Pharmacy graduate awarded national recognition for pioneering research in genetics

Health care reform will lead more people to seek cancer prevention and risk-reduction services

Cytheris initiates ORVACS Phase II clinical trial to study HIV infection

New research coalition to design first human trial of mosaic HIV vaccine candidate

Micronics to advance PanNAT system for molecular diagnosis of infectious pathogens

NeurogesX plans U.S. label expansion for Qutenza in HIV-associated neuropathy

Egg allergy is no reason to avoid 2010-2011 flu vaccination

UCB presents P3, P4 clinical trial data for Crohn's disease at ACG Scientific Meeting

BARACLUDE sNDA receives FDA approval for treatment of CHB patients with decompensated liver disease

GeoVax Labs contributes article for HIV vaccine

NanoViricides' President delivers speech at ASNM Second Annual Conference

Major advance in treatment of brain disorders with external genes

ACG meeting to exhibit Cimzia data for Crohn's disease treatment

Biogen, Elan announce clinical utility data of two-step ELISA to detect anti-JCV antibodies

Royal Cornwall Hospital receives grant to study Hepatitis E

Silver studded bacteria could help treat common cold and flu

CDC: Hispanics more likely to have HIV than whites, but live longer

OTIS urges pregnant women to get vaccinated against influenza

A new way of characterising biomolecules eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Newsletters you may be interested in